Loading stock data…
$14.88-0.44 (-2.87%)
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Delcath Systems, Inc. in the Healthcare sector is trading at $14.97 with a market capitalization of $563M. Wall Street consensus targets $24.00 (5 analysts), implying a +60.3% move over the next 12 months. The stock is currently 14% below its 52-week high of $17.42, remaining 23.8% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $29.13M↑ | $24.99M↑ | $20.73M↑ | $20.56M↓ | $24.16M |
| Gross Profit | $26.15M↑ | $21.26M↑ | $17.72M↓ | $17.94M↓ | $20.84M |
| Operating Income | $2.40M↑ | -$1.64M↑ | -$2.18M↓ | -$388,000↓ | $2.59M |
| Net Income | $2.67M↑ | -$1.07M↑ | -$1.90M↓ | $830,000↓ | $2.70M |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delive...